Market Research Industry Today
Huntington's Disease Market Growth Anticipated by 2032 | Major Players: Prilenia Therapeutics, Ionis Pharmaceuticals, Annexon, Vaccinex, Neurocrine Biosciences, SAGE Therapeutics, PTC Therapeutics, WaVe life Sciences, Novartis, Neurimmune Therapeutics
In the market landscape of Huntington's Disease, an impressive surge is expected during the study period spanning 2019 to 2032, according to latest report titled “Huntington's Disease Market Insights, Epidemiology and Market Forecast 2032” from DelveInsight.
The expansion of the Huntington’s disease market is anticipated to primarily stem from the introduction of innovative emerging treatments, a growing prevalence of the condition, an aging population, heightened efforts in research and development, and the introduction of genetic testing.
The Huntington's Disease market report sheds light on Huntington's Disease current treatment practices, upcoming drugs in the Huntington's Disease pipeline, market shares of individual therapies, and the anticipated trajectory of the Huntington's Disease market size from 2019 to 2032 across the 7MM (the United States, the EU-4 comprising Italy, Spain, France, and Germany, the United Kingdom, and Japan).
Driving Forces Behind the Huntington's Disease Market Growth
The growth of the Huntington’s disease market is expected to be mainly driven by entry of innovative emerging therapies, rising prevalence, and geriatric population, increasing initiatives for R&D, and the advent of genetic testing.
Discover the Anticipated Evolution and Growth of the Market @ Huntington's Disease Therapeutics Market Forecast
Therapeutic Advancements and Emerging Treatments:
- Huntington's Disease Clinical Trial Progression: The market is set to experience significant growth, driven by the progression of emerging therapies expected for launch between 2023 and 2032. Pioneering companies, including Prilenia Therapeutics, Ionis Pharmaceuticals, Annexon, Vaccinex, Neurocrine Biosciences, SAGE Therapeutics, PTC Therapeutics, WaVe life Sciences, Novartis, Neurimmune Therapeutics, SOLA Biosciences, UniQure Biopharma, Roche, Annexon, Inc., Azevan Pharmaceuticals, SOM Innovation Biotech SA, Asklepios BioPharmaceutical, Luye Pharma Group Ltd., BrainStorm Cell Therapeutics, Voyager Therapeutics, Passage Bio, Locana Bio, Ceptur Therapeutics, Enzerna Biosciences, AFFiRiS AG, Arvinas, Atalanta Therapeutics, Anima Biotech, and others, are actively engaged in developing novel drugs for potential market entry.
- Huntington's Disease Innovative Therapies: Ongoing research and development activities are fostering the introduction of innovative therapies designed to address the signs and symptoms of Huntington's Disease. Therapies such as Pridopidine, Tominersen, ANX-005, Pepinemab, Valbenazine, SAGE-718, PTC-518, WVE-003, AMT 130, Branaplam, NI-302, SOL-176, RO7234292, ANX005, SRX246, Bevantolol, SOM3355, BV-101 Gene Therapy, LPM3770164, Passage Bio Research Project, Huntington disease Research Project, BrainStorm Research Project, Locana Huntington disease Research Project, Ceptur Huntington Research Project, HTT RNA Research project, mHTT Research Project, AFFiRiS Huntington Research Project, HTT Research Project, Anima Biotech mHTT Research Project, and others are driving the Huntington's Disease market.
Huntington's Disease Market Dynamics
The first was tetrabenazine, which was approved by the US FDA in 2008 based on the TETRA study. This drug issold as XENAZINE by Lundbeck. The second was deutetrabenazine (AUSTEDO; deuterated version oftetrabenazine), which was approved by the US FDA for for treating chorea associated with Huntington’s disease.XENAZINE was the first drug ever approved in the US for the treatment of a Huntington’s disease symptom. Thismedication was approved with a premium price tag in the US due to its Orphan Drug designation. XENAZINE hassignificant side effects such as somnolence, insomnia, Parkinsonism, severe depression, fatigue, anxiety, andirritability. According to DelveInsight's analysts, tetrabenazine has notable flaws that Teva's AUSTEDOcouldpotentially address. While AUSTEDO has been designated a new molecular entity and an orphan drug, it wasapproved through the 505(b)(2) pathway with tetrabenazine as the Reference Listed Drug (RLD). INGREZZAbyNeurocrine is the third and the most recent drug to be approved for treating adults with chorea associated withHuntington’s disease.
Apart from these available pharmacological treatment options, non-pharmacological treatment includespsychotherapy (to help with behavioral problems and develop coping strategies), speech therapy(to help withslurred speech or trouble swallowing), physical therapy (such as walking), and occupational therapy(activitiesusing the hands). Even after all these options, a patient cannot survive and dies after some years of symptomsonset. Individuals with the adult-onset form of Huntington’s disease usually live about 15–20 years after signs andsymptoms begin.
Huntington's Disease Treatment Market
Lack of approved therapy is not just a limitation for the patients but for the pharma giants as well.Undoubtedly, companies are trying to do their part by developing much needed therapies, however, the highfailure rate of emerging therapies in Huntington’s disease is the major barrier. Not just one or two, but severalcandidate have failed so far. Both the developer and Huntington’s community was optimistic about fewcandidate which eventually turned out to be the opposite. The biggest blow came with the failure of latestage candidate tominersen.
Recently, Wave Life Sciences announced that their two antisense oligonucleotides (ASOs) in Phase I/II studiesin Huntington’s disease patients did not successfully reduce mutant huntingtin levels, hence the companydecided to discontinued those products. Roche/Ionis antisense asset tominersenhad the same fate. Thefailure of Roche and Ionis’s late-stage candidate tominersen had already cast a doubt on Wave’s approach.Development and approval of a novel therapy that treat Huntington’s disease is a major unmet need, and atpresent, a handful of companies are working toward that goal.
Huntington's Disease Market Report Features
Geography Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Study Period: 2019-2032
Huntington's Disease Market Size: USD XX million in 2032
Key Huntington's Disease Companies: Prilenia Therapeutics, Ionis Pharmaceuticals, Annexon, Vaccinex, Neurocrine Biosciences, SAGE Therapeutics, PTC Therapeutics, WaVe life Sciences, Novartis, Neurimmune Therapeutics, SOLA Biosciences, UniQure Biopharma, Roche, Annexon, Inc., Azevan Pharmaceuticals, SOM Innovation Biotech SA, Asklepios BioPharmaceutical, Luye Pharma Group Ltd., BrainStorm Cell Therapeutics, Voyager Therapeutics, Passage Bio, Locana Bio, Ceptur Therapeutics, Enzerna Biosciences, AFFiRiS AG, Arvinas, Atalanta Therapeutics, Anima Biotech, and others.
Leading Huntington's Disease Companies and Emerging Drugs: Pioneering companies such as Prilenia Therapeutics, Ionis Pharmaceuticals, Annexon, Vaccinex, Neurocrine Biosciences, SAGE Therapeutics, PTC Therapeutics, WaVe life Sciences, Novartis, Neurimmune Therapeutics, SOLA Biosciences, UniQure Biopharma, Roche, Annexon, Inc., Azevan Pharmaceuticals, SOM Innovation Biotech SA, Asklepios BioPharmaceutical, Luye Pharma Group Ltd., BrainStorm Cell Therapeutics, Voyager Therapeutics, Passage Bio, Locana Bio, Ceptur Therapeutics, Enzerna Biosciences, AFFiRiS AG, Arvinas, Atalanta Therapeutics, Anima Biotech, among others, are actively developing novel drugs for potential entry into the Huntington's Disease market.
Huntington's Disease Therapeutic Landscape: Key therapies identified for Huntington's Disease treatment include Pridopidine, Tominersen, ANX-005, Pepinemab, Valbenazine, SAGE-718, PTC-518, WVE-003, AMT 130, Branaplam, NI-302, SOL-176, RO7234292, ANX005, SRX246, Bevantolol, SOM3355, BV-101 Gene Therapy, LPM3770164, Passage Bio Research Project, Huntington disease Research Project, BrainStorm Research Project, Locana Huntington disease Research Project, Ceptur Huntington Research Project, HTT RNA Research project, mHTT Research Project, AFFiRiS Huntington Research Project, HTT Research Project, Anima Biotech mHTT Research Project, and more.
Huntington's Disease Overview:
Huntington's disease is a hereditary neurological disorder that progressively affects brain function, leading to various physical, cognitive, and psychiatric symptoms. It is caused by a mutation in the HTT gene, leading to the production of a faulty protein called huntingtin, which damages nerve cells in the brain.
Huntington's disease symptoms: Huntington's disease symptoms typically start between the ages of 30 and 50, although they can appear at any age. Early signs might include involuntary movements (chorea), difficulty with coordination and balance, cognitive decline, mood changes, and psychiatric symptoms such as depression or irritability. As the disease advances, individuals may experience worsening movement, cognitive decline, and behavioral changes.
Huntington's disease genetic inheritance: Huntington's disease is an autosomal dominant genetic disorder, meaning that a child has a 50% chance of inheriting the mutated gene from a parent with the condition. If inherited, the child will eventually develop Huntington's disease, although the onset and severity can vary.
Huntington's disease progression: Huntington's disease is a progressive condition, and symptoms typically worsen over time. Early stages may involve subtle changes in movement and behavior, while later stages can result in significant physical disability and cognitive impairment.
Huntington's disease diagnosis: Diagnosis of Huntington's disease involves a combination of medical history, neurological examination, genetic testing to confirm the presence of the mutated HTT gene, and assessment of symptoms. Genetic counseling is often recommended for individuals considering testing due to the implications of a positive result.
Huntington's disease treatment: There is currently no cure for Huntington's disease, and treatments focus on managing symptoms to improve the individual's quality of life. Medications may help control movement disorders, manage psychiatric symptoms, or address other specific symptoms. Therapies like physical and occupational therapy, speech therapy, and counseling can also be beneficial in managing symptoms and providing support.
Key Facts Huntington's Disease Market Report:
- Key players such as Prilenia Therapeutics, Ionis Pharmaceuticals, Annexon, Vaccinex, Neurocrine Biosciences, SAGE Therapeutics, PTC Therapeutics, WaVe life Sciences, Novartis, Neurimmune Therapeutics, SOLA Biosciences, UniQure Biopharma, Roche, Annexon, Inc., Azevan Pharmaceuticals, SOM Innovation Biotech SA, Asklepios BioPharmaceutical, Luye Pharma Group Ltd., BrainStorm Cell Therapeutics, Voyager Therapeutics, Passage Bio, Locana Bio, Ceptur Therapeutics, Enzerna Biosciences, AFFiRiS AG, Arvinas, Atalanta Therapeutics, Anima Biotech, and others are investigating its candidates for Huntington's Disease.
- Huntington's Disease pipeline includes the therapies such as Pridopidine, Tominersen, ANX-005, Pepinemab, Valbenazine, SAGE-718, PTC-518, WVE-003, AMT 130, Branaplam, NI-302, SOL-176, RO7234292, ANX005, SRX246, Bevantolol, SOM3355, BV-101 Gene Therapy, LPM3770164, Passage Bio Research Project, Huntington disease Research Project, BrainStorm Research Project, Locana Huntington disease Research Project, Ceptur Huntington Research Project, HTT RNA Research project, mHTT Research Project, AFFiRiS Huntington Research Project, HTT Research Project, Anima Biotech mHTT Research Project, and others.
- Som Biotech’s Phase II candidate SOM3355 (bevantolol) is a VMAT2 inhibitor being investigated for chorea associated with Huntington's disease. According to the company, SOM3355 differs from tetrabenazine in interaction with VMAT2 and inhibition of VMAT1, resulting in a balanced shift in monoamine signaling that alleviates motor symptoms of Huntington's disease while maintaining mental well-being. In October 2021, SOM Biotech announced that the US FDA had granted Orphan Drug Designation (ODD) for SOM3355 for the treatment of chorea movements in Huntington’s disease.
- In 2022, Stage II accounted for the highest number of diagnosed prevalent cases of Huntington’s disease. Whereas, Stage V accounted for the lowest number of cases.
Huntington's Disease Epidemiology Segmentation:
“In 2022, the age group of ≥60 accounted for approximately 50% of the total diagnosed prevalent cases of Huntington’s disease in the 7 MM.”
- As per DelveInsight’s analysis, in 2022, the total prevalentcases of Huntington’s disease, were approximately80,800cases in the 7MM, which are expected to increase duringthe forecast period, i.e., 2023-2032.
- As per DelveInsight’s analysis, in 2022, the total prevalentcases of Huntington’s disease, were approximately80,800cases in the 7MM, which are expected to increase duringthe forecast period, i.e., 2023-2032.
- In 2022, the prevalent cases of chorea associatedHuntington’s disease were around 72,700in the 7MM.
The Huntington's Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
• Total Prevalence of Huntington's Disease
• Prevalent Cases of Huntington's Disease by severity
• Gender-specific Prevalence of Huntington's Disease
• Type-specific Prevalence of Huntington's Disease
• Age-specific Prevalence of Huntington's Disease
• Diagnosed Cases of Huntington's Disease
DelveInsight's comprehensive report provides a thorough exploration of the Huntington's Disease market, covering key Huntington's Disease players, emerging Huntington's Disease therapies, treatment dynamics, and market challenges.
For in-depth insights, access the full report @ Huntington's Disease Market Outlook 2032
DelveInsight's report offers comprehensive insights, market analysis, and forecasts aiding leading companies in strategic decision-making for the Huntington's Disease market landscape.
- Gain Competitive Edge in Indication Market : Understand the current landscape of the Huntington's Disease market, including the competitive environment, key companies developing drugs for Huntington's Disease , and their strategies. By analyzing market dynamics, treatment approaches, and emerging therapies, stakeholders can identify opportunities to position themselves effectively, gaining a competitive edge over others.
- Identify Market Gaps and indication market opportunities : Analyzing epidemiological trends, country wise patient journeys and existing tretment practices can helps in identifying gaps and opportunities within the Huntington's Disease market. This involves recognizing areas where current treatments may be insufficient or where there is an unmet need. The report is curated by taking account of various KOLs dealing with Huntington's Disease. Identifying these gaps allows stakeholders to explore new therapeutic avenues, potentially leading to the development of novel treatments that address specific market needs and price their emerging products strategically to gain a competitive edge.
- Strategic decision making : Armed with insights from epidemiological and market forecasts, stakeholders can make informed and strategic decisions. This may involve deciding on research and development investments, portfolio expansion, pricing - reimbursement strategies, partnerships, or other strategic moves. Understanding the market dynamics enables stakeholders to align their goals with the prevailing trends and future projections.
- Plan RoadMap to Success : Through this report the leading companies can set short-term and long-term goals, define strategies for market penetration, and outline steps for product development or market expansion. A well-informed roadmap ensures that stakeholders navigate the complexities of the Huntington's Disease market with clarity and purpose.
Related Reports:
Huntington's Disease Epidemiology Forecast
Huntington's Disease Epidemiology Forecast report delivers an in-depth understanding of the Huntington's Disease, historical and forecasted epidemiology in the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Huntington's Disease Pipeline Insight
Huntington's Disease Pipeline Insight report provides comprehensive insights about companies and pipeline drugs in the Huntington's Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.
Healthcare Consulting and Market Research Services by DelveInsight
Discover how DelveInsight’s comprehensive analysis and proactive strategies facilitated a US-based pharmaceutical client’s triumphant entry into the European biosimilar landscape. Download Pharma Go-to-Market Case Study.
Trending Reports by DelveInsight
Functional Constipation Market
https://www.delveinsight.com/report-store/chronic-constipation-market
Lebers Hereditary Optic Neuropathy Lhon Market
https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market
Gastric Neuroendocrine Tumors Market
https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market
Immune Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market
Visceral Pain Associated With GI Disorders Market
https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market
Bullous Pemphigoid Market
https://www.delveinsight.com/report-store/bullous-pemphigoid-market
Cyclin-dependent Kinase-like 5 Deficiency Disorder Market https://www.delveinsight.com/infographics/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market
Myocarditis Market
https://www.delveinsight.com/report-store/myocarditis-market
Recurrent Blood Clots Market
https://www.delveinsight.com/report-store/recurrent-blood-clots-thrombophilia-market
Zollinger-ellison Syndrome Market
https://www.delveinsight.com/report-store/zollinger-ellison-syndrome-market
Age-related Hearing Loss Medical Device Market
https://www.delveinsight.com/blog/age-related-hearing-loss-device-market
Heart Sounds Sensors Market
https://www.delveinsight.com/report-store/heart-sounds-sensors-electronic-stethoscope-market
Hypoplastic Left Heart Syndrome Hlhs Market
https://www.delveinsight.com/report-store/hypoplastic-left-heart-syndrome-market
Infectious Arthritis/Septic Arthritis Market
https://www.delveinsight.com/report-store/infectious-arthritisseptic-arthritis-market
Plasmacytoma Market
https://www.delveinsight.com/report-store/plasmacytoma-market
Agoraphobia Market
https://www.delveinsight.com/report-store/agoraphobia-market
Clinically Isolated Syndrome CIS Market
https://www.delveinsight.com/report-store/clinically-isolated-syndrome-cis-market
Fucosidosis Market
https://www.delveinsight.com/report-store/fucosidosis-market
Major Depressive Disorder Market
https://www.delveinsight.com/report-store/major-depressive-disorder-market
Neuronal Ceroid-lipofuscinoses Market
https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market
Orthotic Devices Market
https://www.delveinsight.com/report-store/orthotic-devices-market
About DelveInsight:
DelveInsight is a prominent business consultant and market research firm specializing in the life sciences sector. With a focus on supporting pharmaceutical companies, DelveInsight provides end-to-end solutions to enhance their performance.
Connect with DelveInsight:
Contact Us:
Kritika Rehani
Team Lead, Marketing
krehani@delveinsight.com
+91-9650213330
Share on Social Media
Other Industry News
Ready to start publishing
Sign Up today!
